QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)

Revance Therapeutics (RVNC) Earnings Date, Estimates & Call Transcripts

$6.77
-0.17 (-2.45%)
(As of 11/30/2023 ET)
Compare
Today's Range
$6.74
▼
$7.09
50-Day Range
$5.81
▼
$13.01
52-Week Range
$5.72
▼
$37.98
Volume
1.60 million shs
Average Volume
1.63 million shs
Market Capitalization
$594.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.33
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Feb. 27Estimated
Actual EPS
(Nov. 8)
-$0.74 Beat By $0.28
Consensus EPS
(Nov. 8)
-$1.02
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RVNC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RVNC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Revance Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.99)($0.73)($0.86)
Q2 20232($0.91)($0.70)($0.81)
Q3 20232($1.43)($0.81)($1.12)
Q4 20232($0.81)($0.70)($0.76)
FY 20238($4.14)($2.94)($3.54)
Q1 20242($0.60)($0.56)($0.58)
Q2 20242($0.59)($0.51)($0.55)
Q3 20242($0.66)($0.35)($0.51)
Q4 20242($0.55)($0.37)($0.46)
FY 20248($2.40)($1.79)($2.10)

RVNC Earnings Date and Information

Revance Therapeutics last posted its earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.28. The business had revenue of $56.78 million for the quarter, compared to analyst estimates of $58.49 million. Revance Therapeutics has generated ($4.99) earnings per share over the last year (($4.99) diluted earnings per share). Earnings for Revance Therapeutics are expected to grow in the coming year, from ($3.05) to ($2.09) per share. Revance Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.

Revance Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/27/2024
Estimated)		------- 
11/8/2023Q3 2023($1.02)($0.74)+$0.28$0.15$58.49 million$56.78 million
8/8/2023Q2 2023($0.72)($0.80)($0.08)($0.80)$58.71 million$58.13 million    
5/9/2023Q1 2023($0.75)($0.74)+$0.01($0.74)$46.21 million$49.33 million      
2/28/2023Q4 2022($1.04)($1.82)($0.78)($1.82)$45.10 million$49.90 million      
11/8/2022Q3 2022($0.85)($1.17)($0.32)($1.17)$28.76 million$29.02 million
8/9/2022Q2 2022($0.91)($0.88)+$0.03($0.88)$27.64 million$28.37 million
5/10/2022Q1 2022($0.91)($0.94)($0.03)($0.94)$23.55 million$25.26 million
2/28/2022Q4 2021($0.98)($0.93)+$0.05($0.93)$24.56 million$25.95 million    
11/9/2021Q3 2021($1.15)($1.10)+$0.05($1.10)$20.03 million$19.75 million    
8/5/2021Q2 2021($1.14)($1.07)+$0.07($1.07)$16.68 million$18.80 million
5/10/2021Q1 2021($1.19)($1.08)+$0.11($1.08)$12.44 million$13.30 million    
2/21/2021Q4 2020($1.25)($1.24)+$0.01($1.24)$10.16 million$11.13 million    












Revance Therapeutics Earnings - Frequently Asked Questions

When is Revance Therapeutics's earnings date?

Revance Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off last year's report dates. Learn more on RVNC's earnings history.

Did Revance Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Revance Therapeutics (NASDAQ:RVNC) reported ($0.74) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.02) by $0.28. Learn more on analysts' earnings estimate vs. RVNC's actual earnings.

How much revenue does Revance Therapeutics generate each year?

Revance Therapeutics (NASDAQ:RVNC) has a recorded annual revenue of $132.57 million.

How much profit does Revance Therapeutics generate each year?

Revance Therapeutics (NASDAQ:RVNC) has a recorded net income of -$356.42 million. RVNC has generated -$4.99 earnings per share over the last four quarters.

What is Revance Therapeutics's EPS forecast for next year?

Revance Therapeutics's earnings are expected to grow from ($3.05) per share to ($2.09) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:RVNC) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -